tradingkey.logo

Lixte rises after buying UK firm to enter proton therapy cancer care

ReutersNov 25, 2025 1:53 PM

Shares of drug developer Lixte Biotechnology LIXT.O rise 7% to $4.78 premarket

Co says it acquired Liora Technologies Europe, which develops proton therapy systems for cancer treatment

Liora's flagship "LiGHT System" aims to deliver high-precision proton therapy at lower cost and fewer sessions - LIXT

LIXT says system installed at UK's STFC Daresbury Lab; plans to create a center of excellence for cancer care

Deal expands co beyond cancer drugs into radiotherapy; complements trials of its cancer therapy LB-100 for ovarian and colon cancer

Proton therapy is a type of radiation treatment for cancer that uses protons instead of X-rays to target tumors

Up to last close, stock up ~120% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI